Medicare AdvantageJanuary 31, 2024
Notification of specialty pharmacy medical step therapy updates
This is a courtesy notice as there is no change to current status of Eylea HD in the Medical Step Therapy Program. The step criteria for anti-vascular endothelial growth factor (VEGF) inhibitors found in Clinical Criteria document CC-0072 will formally list Eylea HD as a preferred product.
Clinical UM Guidelines are publicly available on the provider website. Visit the Clinical Criteria page to search for specific criteria.
| Clinical UM Guidelines | Preferred drug(s) | Nonpreferred drug(s) |
| CC-0072 | Avastin Byooviz Cimerli Eylea Eylea HD Lucentis Vabysmo | Beovu Macugen |
Through genuine collaboration, we can simplify access to care and help you deliver high-quality, equitable healthcare.
Anthem BC Health Insurance Company is the trade name of Anthem Insurance Companies, Inc. Anthem Blue Cross is the trade name of Blue Cross of California. Anthem Blue Cross, Anthem Blue Cross Life and Health Insurance Company, and Anthem BC Health Insurance Company are independent licensees of the Blue Cross Association. Anthem is a registered trademark of Anthem Insurance Companies, Inc.
CABC-CR-046816-23-CPN45766
PUBLICATIONS: March 2024 Provider Newsletter
To view this article online:
Or scan this QR code with your phone